BioHarvest Sciences reveals cannabis composition profile
BioHarvest Sciences unveils the composition profile of its full-spectrum cannabis produced via Bio-Plant CELLicitation.
bioharvest.comCrawled Nov 18, 2026
BioHarvest Sciences unveils the composition profile of its full-spectrum cannabis produced via Bio-Plant CELLicitation.
BioHarvest conducts clinical studies on health-promoting phytonutrients from red grape cells for skin, eye, liver, and brain health.
BioHarvest’s pipeline focuses on polyphenols from grape, olive, and pomegranate cells, using Botanical Synthesis to create unique compositions.
BioHarvest’s CDMO services enable companies to develop patented plant-based molecules using Botanical Synthesis technology.
BioHarvest’s Botanical Synthesis process combines botanical elements to form non-GMO, reproducible compositions.
BioHarvest develops non-GMO botanical compositions through a reproducible, planet-friendly Botanical Synthesis process.
BioHarvest Sciences shares 2025 milestone achievements with shareholders in a letter from CEO Ilan Sobel.
Robust 41% Year-Over-Year Revenue Growth, Driven by Strong Core Capsule and New Product Sales Rehovot, Israel – August 11, 2025 - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) (“BioHarvest” or the “Company”), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the second quarter ended June 30,
New research analysis affirms the addition of the following structure function claims for VINIA according to FDA Guidelines for Dietary Supplements:
BioHarvest introduces single-dose VINIA Daily Chews, expanding product versatility for CDMO partners.
BioHarvest completes development and commercial-scale manufacturing of a Verbascoside composition using its Botanical Synthesis platform.
BioHarvest Sciences prioritizes cash preservation and focuses CDMO resources on advanced programs with near-term manufacturing potential.
BioHarvest Sciences authorizes a share repurchase program to support its growth strategy.
BioHarvest Sciences announces its third-quarter 2026 financial results release date.
BioHarvest and Tate & Lyle collaborate on a next-generation sweetening solution using Botanical Synthesis technology.
BioHarvest Sciences introduces its executive team, including CEO and Chairman Dr. Zaki Rakib.
Sustainability We are committed to leaving a small footprint. Our sustainable technology has unparalleled advantages for the environment. Home Our Competitive Advantage Sustainability BioHarvest Sciences wins The Business Intelligence Group 2022 Sustainability Leadership Award “By delivering the benefits of plants using a fraction of the energy, water, and land that agriculture would, we see the
BioHarvest Sciences provides contact details for investor inquiries, media, and customer service.
BioHarvest FAQ Home Investors Investor FAQ How do I invest in BioHarvest Sciences? BioHarvest Sciences is a publicly listed company, listed on the Nasdaq Global Market under the symbol “BHST”. In Europe, BioHarvest trades on the Deutsche Boerse Frankfurt Exchange under the symbol “8MV” All common shares purchased in either of these markets are for
BioHarvest’s Botanical Synthesis technology enables development of patentable plant-based molecules, branded as BIOLOGICS+.